Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol-Myers Squibb's BuSpar

Executive Summary

Patent infringement dispute with Danbury over the anxiolytic agent remanded to Manhattan federal court for full trial. On April 13, a D.C. federal appeals court overturned a June 30, 1993 lower court decision that granted a summary judgment in favor of Danbury ('The Pink Sheet" July 12, 1993, T&G-12). The lower court had ruled that BMS' U.S. patent No. 4,182,763 for buspirone was invalid due to anticipation by another earlier patent granted to the company, 3,976,776. The appellate court rejected the lower court's ruling that the '776 patent, which describes buspirone as having "tranquilizing effects," anticipated the '763 patent, which claims the use of buspirone as a treatment for neurotic anxiety. BMS filed suit against Danbury for patent infringement in September 1992 after the generic drug firm submitted an ANDA for buspirone. The '763 patent for buspirone expires Jan. 8, 1999

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts